Aarkstore - Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015
Summary
Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-drug conjugates profile which gives core information of the targets, mechanism of action, development partner, Technology partner, monoclonal antibody used, linker used and cytotoxic drug with the descriptive information of the technologies. The Report also provides the assessment of the company’s undergone collaborations for technology and monoclonal antibody and also gives insights over the pre-clinical and clinical data. The Report has also assessed the ADCs on geographical distribution based on the country and region.
Report Facts
Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. The ongoing research on this therapy will replace the chemotherapeutics treatments in the near future thereby reducing its toxic side effects. Billions of dollars are spent on the chemotherapy treatments annually. Different Biotechnology companies and Pharma Companies are collaborating in all area of ADCs like linker technology, antibody production and conjugation process. Seattle Genetics’s Brentuximab vedotin and Roche’s trastuzumab emtansine are the only ADCs approved which have together made USD 523 millions sales in 2013. There are total 264 ADCs in pipeline with 253 ADCS are developing only for Oncology indications. Pipeline is very rich with four potential drugs in Phase III stage out of which Kadcyla and Adcetris are undergoing clinical studies for different conditions. According to DelveInsight Analysis, North America has the highest number of development in ADCs with 161 ADCs and 65 Active companies...